Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Diabetic cognitive dysfunction (DCD) is a prevalent complication of diabetes, characterized by progressive cognitive decline. Current pharmacological interventions have limited therapeutic efficacy in managing this condition. Huoshan large - leaf yellow tea (HLYT), derived from Camellia sinensis leaves, has demonstrated dual pharmacological properties in both glycemic regulation and cognitive enhancement, suggesting its potential as a preventive and therapeutic agent for DCD.
Purpose: The main purpose of this study was to clarify the regulatory effect of HLYT on DCD and explore its underlying mechanisms.
Study Design: The research encompassed a comprehensive multi-phase investigation. Network pharmacological analysis identified HLYT's key target genes for DCD. Molecular docking screened hub target genes, which were further verified by molecular dynamic (MD) simulations. High-performance liquid chromatography (HPLC) quantified HLYT's active components for setting animal experiment dosages. A DCD model was established in rats by feeding them a high - fat diet and injecting streptozotocin (STZ). Subsequently, HLYT was administered to the rats via intragastric gavage for intervention. The results of this intervention were then verified through relevant animal experiments.
Results: Utilizing an integrated approach of network pharmacology and molecular docking, five pivotal target genes (Adora2a, Mapk8, Stat3, Vcam1, Edn1) were identified as the primary molecular targets of HLYT in DCD pathogenesis. Quercetin, kaempferol, caffeine, theobromine, and EGCG in HLYT exhibited significant binding affinities with these targets. The results of animal experiment have shown that HLYT can alleviate neuronal damage and cognitive dysfunction, reduce the levels of IL-6 and IL-1β in the serum and brain tissue in DCD rats. Furthermore, it can also inhibit the expression of Adora2a, Mapk8, Stat3, Vcam1, and Edn1 mRNA as well as the expression of STAT3, ADORA2A, JNK1, ET1, and VCAM1 proteins.
Conclusion: HLYT has a significant protective effect on DCD in rats by regulating Adora2a, Mapk8, Stat3, Vcam1, and Edn1 genes, suggesting that it has remarkable clinical potential in the treatment of DCD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2025.156923 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanistic Insights and Translational Therapeutics of Neurovascular Unit Dysregulation in Vascular Cognitive Impairment.
J Integr Neurosci
August 2025
Key Laboratory of Modern Toxicology of Ministry of Education; School of Basic Medical Sciences, Nanjing Medical University, 211166 Nanjing, Jiangsu, China.
Cognitive impairment represents a progressive neurodegenerative condition with severity ranging from mild cognitive impairment (MCI) to dementia and exerts significant burdens on both individuals and healthcare systems. Vascular cognitive impairment (VCI) represents a heterogeneous clinical continuum, spanning a spectrum from subcortical ischemic VCI (featuring small vessel disease, white matter lesions, and lacunar infarcts) to mixed dementia, where vascular and Alzheimer's-type pathologies coexist. While traditionally linked to macro- and microvascular dysfunction, the mechanisms underlying VCI remain complex.
View Article and Find Full Text PDFBrain Insulin Signaling Pathway Regulation of Hippocampal Neuroplasticity in Neurocognitive Disorders: Mechanisms and Therapeutic Implications.
J Integr Neurosci
August 2025
Department of Anesthesiology, The First Medical Center of Chinese PLA General Hospital, 100853 Beijing, China.
Neurocognitive disorders represent a significant global health challenge and are characterized by progressive cognitive decline across conditions including Alzheimer's disease, mild cognitive impairment, and diabetes-related cognitive impairment. The hippocampus is essential for learning and memory and requires intact neuroplasticity to maintain cognitive function. Recent evidence has identified the brain insulin signaling pathway as a key regulator of hippocampal neuroplasticity through multiple cellular processes including synaptic plasticity, neurotransmitter regulation, and neuronal survival.
View Article and Find Full Text PDFAlleviating the NF-κB/NLRP3 pathway-mediated pyroptosis and ameliorating the cognitive function of aged mice post partial hepatectomy by increasing the Bmal1 level via subanesthetic doses of ketamine.
Transl Neurosci
January 2025
Department of Anesthesia, The Second Affiliated Hospital of Xi'an JiaoTong University, 157 Xi Wu Road, Xi'an, 710004, Shaanxi, China.
Background: As a non-competitive blocker of the -methyl-d-aspartate receptor, ketamine is widely used for anesthesia and pain relief in clinical settings. However, certain neurological side effects may appear if it is used for the long term. According to clinical observations, anesthetic doses of ketamine trigger postoperative neurocognitive dysfunction in elderly patients, while subanesthetic doses of ketamine suppress the postoperative neuronal pyroptosis in the hippocampus, ameliorating the cognitive function.
View Article and Find Full Text PDFStructural and functional neural correlates of sensorimotor deficits in progression of hepatic encephalopathy.
Magn Reson Lett
May 2025
Department of Medical Imaging, Tianjin First Central Hospital, Tianjin, 300192, China.
Hepatic encephalopathy (HE) is a neurological condition that occurs as a complication of liver dysfunction that involves sensorimotor symptoms in addition to cognitive and behavioral changes, particularly in cases of severe liver disease or cirrhosis. Previous studies have reported spatially distributed structural and functional abnormalities related to HE, but the exact relationship between the structural and functional alterations with respect to disease progression remains unclear. In this study, we performed surface-based cortical thickness comparisons and functional connectivity (FC) analyses between three cross-sectional groups: healthy controls (HC, = 51), patients with minimal hepatic encephalopathy (MHE, = 50), patients with overt hepatic encephalopathy (OHE, = 51).
View Article and Find Full Text PDFProbiotic Supplementation Improves the Clinical Measures of Cognition in Patients With Mild Cognitive Impairment.
Cureus
August 2025
Medical Education, Western Atlantic University School of Medicine, Freeport, BHS.
Mild cognitive impairment progresses slowly and may be reversible, providing a window of opportunity for intervention before it progresses to Alzheimer's disease, at which point treatments, at best, ameliorate symptoms with little efficacy towards delaying disease progression. The gut and brain communicate through the gut-brain axis, and derangement of the gut microbiome has been shown to promote neuroinflammation, a process intricately linked to pathological progression to mild cognitive impairment and subsequent neurocognitive diseases. In preclinical trials, probiotics modulated the gut microbiome in a way that was neuroprotective.
View Article and Find Full Text PDF